Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy versus chemotherapy alone for advanced or recurrent gynecologic malignancies
ChiCTR1900021190Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of anlotinib in vaginal cancer, Cervical Cancer (CC) and uterine cancer (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Disease control rate. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
vaginal cancerCervical Cancer (CC)uterine cancer
Beyond the preview
Go deeper on ChiCTR1900021190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021190.